Atlas Venture has gathered another pot of cash for biotech creation. Less than two years after disclosing a $400 million fund, the Massachusetts-based VC shop has reeled in still more money for its next wave of new startups.
Atlas Venture, a leading early stage venture capital firm investing in groundbreaking biotech innovation, today announced the closing of its thirteenth fund, raising $450 million in an oversubscribed fundraise. With Fund XIII, Atlas Venture will continue working alongside talented entrepreneurs to create and invest in a new set of biotech companies aimed at delivering impactful medicines to patients.
One of the most common questions I get asked is how I got into the business side of the biotech industry, and in particular business development. My career path did not follow a predictable, straight line. I had not set out intending to become a chief business officer at a biotech company. It was a combination of the decisions I made and risks I took over the course of my varied professional experiences that led me where I am today.
By Deanna M. Petersen, CBO of AVROBIO, as part of the From The Trenches feature of LifeSciVC.
For anyone that’s part of a fast paced, growing organization, resilience is the key to thriving. It supports our audacity, ability to tune out the naysayers, and ultimately possess the stamina to prevail. These days, though, it feels increasingly like everything taxes our resilience more than ever before. As organizations, formerly simple things like having an office party draw on our resilience, and already complex things like coordinating global operations certainly do during the pandemic. As individuals, simple things like sending kids to school test our resilience in new ways. Now more than ever, leadership teams need to think about how to cultivate resilience as an organization to be ready for the long journey of fulfilling the mission. This piece shares a few thoughts that our teams and I’ve collected while building organizations that have been resilient to the curveballs the world has thrown our way.
By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC
Third Harmonic Bio has launched from stealth mode with $155 million to develop a single therapy that the Cambridge startup hopes can treat multiple diseases caused by severe allergies and inflammation.